Interestingly, successful achievement of CR/CRi treated with BHA in 6 of 9 FLT3-mutated R/R AML indicated that BHA was effective as a salvage therapy even when sorafenib was of ineffective to R/R AML with FLT3 mutation. The gene discussed is FLT3; the disease is acute myeloid leukemia.